American Cancer Society BrightEdge
Investment Details
Investor Type
Venture Capital
Asset Class Focus
Venture Capital
Stage Focus
Seed, Early Stage, Series A, Series B, Growth, Late Stage
Geographical Focus
United States
Industries Focus
- Healthcare
- Digital Health
- Pharmaceuticals
- Medical Devices
- Diagnostics
- Biotechnology
- Health Services
- Medical Research
- Clinical Trials
- Immunotherapy
- Oncology
- Medical Technology
- Health Equity
- Patient Support
- Cancer Research
Investment Size:
1,000,000 to 50,000,000 USD
Investor Details Founded: 2019
American Cancer Society BrightEdge is the innovation and impact investment arm of the American Cancer Society (ACS), dedicated to accelerating the commercialization of patient-centric innovations across the cancer continuum. By investing in early-stage companies developing cutting-edge cancer-focused therapeutics, diagnostics, devices, and technologies, BrightEdge aims to reduce cancer mortality, end pain and suffering, and advance health equity.
BrightEdge operates at the intersection of investment, innovation, and impact, leveraging ACS's extensive knowledge base from over a century of driving cancer research, public policy, and patient services. The fund strategically invests in entrepreneurial companies to catalyze impactful innovation, with a goal of generating financial returns that can be reinvested to support ACS's lifesaving work. Since its inception, BrightEdge has invested a total of $43 million in 21 companies focused on developing innovations to address critical needs along the cancer care continuum.
BrightEdge's investment strategy is guided by ACS's mission priorities, seeking to achieve mission-driven social impact through its proprietary Cancer Impact Investment Framework. By investing in for-profit, early-stage companies, BrightEdge aims to advance science, reduce disparities, and promote healthcare sustainability, ultimately contributing to the eradication of cancer.
Requirements
- Early-stage companies developing cancer-focused therapeutics, diagnostics, devices, and technologies
Contact
[Official Website Hidden]
[LinkedIn Profile Hidden]
[HQ Location Hidden]
[Email Hidden]
[Contact Number Hidden]
Portfolio Companies
- Checkmate Pharmaceuticals
- Persephoni BioSciences LLC
- Cloverleaf Bio
Mentioned In
-
$24.95
-
$49.95
-
$14.95
-
$39.95
-
$19.95
-
$24.95
-
$299.00
-
$95.00
Claim this Investor
Are you an official representative of American Cancer Society BrightEdge?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim